newsfilter
← Latest News
PR Newswire·

Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study

Johnson & Johnson (NYSE: JNJ) today announced that TREMFYA® (guselkumab) met the primary and major secondary endpoints demonstrating both improvement ...